ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
In vitro activity of furazidin and comparator agents against bacterial isolates from urinary tract infections.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeFurazidin is a nitrofuran derivative used in Eastern Europe (e.g., Latvia, Lithuania and Poland) and Russia for treating uncomplicated urinary tract infections (UTI), while nitrofurantoin, another nitrofuran, is a widely used for this indication. This study (23-ADA-01) evaluated the activity of furazidin, nitrofurantoin, and fosfomycin against bacterial isolates collected between 2020 and 2022 from female UTI patients in 19 European and the Mediterranean countries.
methodsA total of 3,111 isolates were tested for susceptibility to furazidin, nitrofurantoin and fosfomycin using broth microdilution or agar dilution at a monitoring laboratory (JMI Laboratories, North Liberty, Iowa, USA). Minimum inhibitory concentration (MIC) results for antimicrobial agents commonly used to treat UTI, that were previously evaluated as part of the SENTRY Antimicrobial Surveillance Program, were added to the study for evaluation of cross-resistance. Additionally, minimum bactericidal concentration (MBC) testing was performed for 212 isolates.
resultsFurazidin demonstrated high in vitro activity, especially against Escherichia coli (n = 1,758; MIC
conclusionOur study demonstrates that furazidin exhibits potent in vitro activity against a broad spectrum of organisms responsible for UTIs. These data support furazidin as an effective alternative for treatment of UTIs.
Indexed as
Identifiers
41622368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.